Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioptik TechnologyROCO:4161 -0.87%71 FCF Margin % is 39.96% as of Jun. 2026, which is 9193% above its 10-year median of 0.43. GuruFocus rates ROCO:4161 with a GF Score™ of 71/100 and a GF Value™ of NT$29.76 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 813 Medical Devices & Instruments companies, Bioptik Technology ranks better than 73.68% on this metric.
The historical rank and industry rank for Bioptik Technology's FCF Margin % or its related term are showing as below:
ROCO:4161'
s FCF Margin % Range Over the Past 10 Years
Min: -13.9 Med: 0.43 Max: 21.11
Current: 9.47
During the past 13 years, the highest FCF Margin % of Bioptik Technology was 21.11%. The lowest was -13.90%. And the median was 0.43%.
ROCO:4161's FCF Margin % is ranked better than 73.68% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.74
vs ROCO:4161: 9.47
The historical data trend for Bioptik Technology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4161 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Bioptik Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a FCF Margin % of 39.96% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioptik Technology and its competitors. This is 9193% above median its historical median of 0.43. According to the industry distribution chart, Bioptik Technology ranks #214 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Bioptik Technology's FCF Margin % too high?
Bioptik Technology's current FCF Margin % of 39.96% is 9193% above median its 10-year median of 0.43. Based on the distribution chart, Bioptik Technology ranks #214 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #214 out of 813 companies for FCF Margin %. This puts Bioptik Technology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioptik Technology and its competitors. Bioptik Technology's current FCF Margin % is 39.96%, which is 9193% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.76, compared to a current price of NT$22.90 — trading 23.1% below its estimated fair value. The current FCF Margin % is 39.96%, which is 9193% above median its 10-year median of 0.43. Bioptik Technology's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current FCF Margin % is 39.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$22.90 is trading 23.1% below its estimated GF Value™ of NT$29.76.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
FCF Margin %: 39.96% (9193% above median its 10-year median of 0.43)
GF Value™: NT$29.76 vs. price of NT$22.90 (23.1% below fair value)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
71GF Score
Get the complete analysis for ROCO:4161
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
